Protalix BioTherapeutics Inc. PLX

ASE: PLX | ISIN: US74365A1016   17/09/2025
1,870 USD (-4,10%)
(-4,10%)   17/09/2025

30 juni 2022 · Protalix BioTherapeutics Appoints Shmuel "Muli" Ben Zvi, Ph.D. to its Board of Directors · Persbericht

26 mei 2022 · Protalix BioTherapeutics Announces Poster Presentations at the 2022 Program: 7th Update on Fabry Disease · Persbericht

16 mei 2022 · Protalix BioTherapeutics Reports First Quarter 2022 Financial and Business Results · Persbericht

9 mei 2022 · Protalix BioTherapeutics to Announce First Quarter 2022 Financial and Business Results Conference Call on May 16, 2022 · Persbericht

4 april 2022 · Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Topline Results from the 24-Month Phase III BALANCE Clinical Trial of PRX-102 for the Treatment of Fabry Disease · Persbericht

31 maart 2022 · Protalix BioTherapeutics Reports Fiscal Year 2021 Financial and Business Results · Persbericht

24 maart 2022 · Protalix BioTherapeutics to Hold Fiscal Year 2021 Financial and Business Results Conference Call on March 31, 2022 · Persbericht

18 maart 2022 · Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Final Results of the BRIGHT Phase III Clinical Trial Evaluating PRX-102 for the Treatment of Fabry Disease · Persbericht

27 februari 2022 · Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce the Submission of a Marketing Authorization Application to the European Medicines Agency for PRX-102 for the Treatment of Fabry Disease · Persbericht

3 februari 2022 · Protalix BioTherapeutics to Participate in the 18th Annual WORLDSymposium™ 2022 · Persbericht

15 november 2021 · Protalix BioTherapeutics Reports Third Quarter 2021 Financial Results and Provides Financial and Business Update · Persbericht

8 november 2021 · Protalix BioTherapeutics to Release Third Quarter 2021 Financial Results and Provide a Financial and Business Update on November 15, 2021 · Persbericht

15 oktober 2021 · Protalix Biotherapeutics and Chiesi Global Rare Diseases Announce Final Dosing of Last Patient in Phase III BALANCE Clinical Trial PRX-102 for the Treatment of Fabry Disease · Persbericht

11 oktober 2021 · Protalix Biotherapeutics and Chiesi Global Rare Diseases Provide Regulatory Update on PRX-102 for the Treatment of Fabry Disease · Persbericht

26 augustus 2021 · Protalix BioTherapeutics Announces Closing of Private Note Exchange · Persbericht

16 augustus 2021 · Protalix BioTherapeutics Reports Second Quarter 2021 Financial Results and Financial and Business Update · Persbericht

13 augustus 2021 · Protalix BioTherapeutics Announces Private Note Exchange · Persbericht

9 augustus 2021 · Protalix BioTherapeutics to Release Second Quarter 2021 Financial Results and Provide a Financial and Business Update on August 16, 2021 · Persbericht

2 augustus 2021 · Protalix BioTherapeutics Announces Submission of Type A Meeting Request to the FDA · Persbericht

28 juni 2021 · Protalix BioTherapeutics to Participate in a Fireside Chat on June 30, 2021 · Persbericht

Mijn selecties